Logo image of VRTX

VERTEX PHARMACEUTICALS INC (VRTX) Stock Price, Quote, News and Overview

NASDAQ:VRTX - Nasdaq - US92532F1003 - Common Stock - Currency: USD

451.52  +5.37 (+1.2%)

After market: 449.151 -2.37 (-0.52%)

VRTX Quote, Performance and Key Statistics

VERTEX PHARMACEUTICALS INC

NASDAQ:VRTX (6/10/2025, 8:15:38 PM)

After market: 449.151 -2.37 (-0.52%)

451.52

+5.37 (+1.2%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High519.88
52 Week Low377.85
Market Cap115.95B
Shares256.80M
Float256.14M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE21.61
Earnings (Next)07-30 2025-07-30/amc
IPO07-24 1991-07-24


VRTX short term performance overview.The bars show the price performance of VRTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 -2 -4 -6 -8 -10

VRTX long term performance overview.The bars show the price performance of VRTX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 40 60

The current stock price of VRTX is 451.52 USD. In the past month the price increased by 2.77%. In the past year, price decreased by -6.08%.

VERTEX PHARMACEUTICALS INC / VRTX Daily stock chart

VRTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.45 334.73B
AMGN AMGEN INC 14.13 157.78B
GILD GILEAD SCIENCES INC 14.22 136.94B
REGN REGENERON PHARMACEUTICALS 11.82 56.53B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 39.44B
ARGX ARGENX SE - ADR 100.08 35.14B
ONC BEONE MEDICINES LTD-ADR 6.74 28.50B
BNTX BIONTECH SE-ADR N/A 25.70B
NTRA NATERA INC N/A 22.56B
BIIB BIOGEN INC 8.56 19.85B
INSM INSMED INC N/A 16.56B
SMMT SUMMIT THERAPEUTICS INC N/A 16.40B

About VRTX

Company Profile

VRTX logo image Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,100 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Company Info

VERTEX PHARMACEUTICALS INC

50 Northern Avenue

Boston MASSACHUSETTS 02210 US

CEO: Reshma Kewalramani

Employees: 6100

VRTX Company Website

VRTX Investor Relations

Phone: 16173416393

VERTEX PHARMACEUTICALS INC / VRTX FAQ

What is the stock price of VERTEX PHARMACEUTICALS INC today?

The current stock price of VRTX is 451.52 USD. The price increased by 1.2% in the last trading session.


What is the ticker symbol for VERTEX PHARMACEUTICALS INC stock?

The exchange symbol of VERTEX PHARMACEUTICALS INC is VRTX and it is listed on the Nasdaq exchange.


On which exchange is VRTX stock listed?

VRTX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for VERTEX PHARMACEUTICALS INC stock?

40 analysts have analysed VRTX and the average price target is 515.31 USD. This implies a price increase of 14.13% is expected in the next year compared to the current price of 451.52. Check the VERTEX PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is VERTEX PHARMACEUTICALS INC worth?

VERTEX PHARMACEUTICALS INC (VRTX) has a market capitalization of 115.95B USD. This makes VRTX a Large Cap stock.


How many employees does VERTEX PHARMACEUTICALS INC have?

VERTEX PHARMACEUTICALS INC (VRTX) currently has 6100 employees.


What are the support and resistance levels for VERTEX PHARMACEUTICALS INC (VRTX) stock?

VERTEX PHARMACEUTICALS INC (VRTX) has a support level at 448.6 and a resistance level at 458.95. Check the full technical report for a detailed analysis of VRTX support and resistance levels.


Is VERTEX PHARMACEUTICALS INC (VRTX) expected to grow?

The Revenue of VERTEX PHARMACEUTICALS INC (VRTX) is expected to grow by 9.62% in the next year. Check the estimates tab for more information on the VRTX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy VERTEX PHARMACEUTICALS INC (VRTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does VERTEX PHARMACEUTICALS INC (VRTX) stock pay dividends?

VRTX does not pay a dividend.


When does VERTEX PHARMACEUTICALS INC (VRTX) report earnings?

VERTEX PHARMACEUTICALS INC (VRTX) will report earnings on 2025-07-30, after the market close.


What is the Price/Earnings (PE) ratio of VERTEX PHARMACEUTICALS INC (VRTX)?

VERTEX PHARMACEUTICALS INC (VRTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.41).


What is the Short Interest ratio of VERTEX PHARMACEUTICALS INC (VRTX) stock?

The outstanding short interest for VERTEX PHARMACEUTICALS INC (VRTX) is 1.88% of its float. Check the ownership tab for more information on the VRTX short interest.


VRTX Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to VRTX. When comparing the yearly performance of all stocks, VRTX is a bad performer in the overall market: 77.76% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

VRTX Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to VRTX. Both the profitability and the financial health of VRTX get a neutral evaluation. Nothing too spectacular is happening here.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VRTX Financial Highlights

Over the last trailing twelve months VRTX reported a non-GAAP Earnings per Share(EPS) of -0.41. The EPS decreased by -102.42% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -4.32%
ROE -5.99%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%-14.71%
Sales Q2Q%2.96%
EPS 1Y (TTM)-102.42%
Revenue 1Y (TTM)8.98%

VRTX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 75% to VRTX. The Buy consensus is the average rating of analysts ratings from 40 analysts.

For the next year, analysts expect an EPS growth of 6198.7% and a revenue growth 9.62% for VRTX


Ownership
Inst Owners96.16%
Ins Owners0.15%
Short Float %1.88%
Short Ratio2.62
Analysts
Analysts75
Price Target515.31 (14.13%)
EPS Next Y6198.7%
Revenue Next Year9.62%